



Hurt, C. N., Mukherjee, S., Bridgewater, J., Falk, S. J., Crosby, T., McDonald, A., Joseph, G., Staffurth, J., Abrams, R. A., Blazeby, J. M., Bridges, S. J., Dutton, P., Griffiths, G., Maughan, T., & Johnson, C. (2015). Health-Related Quality of Life in SCALOP, a Randomized Phase 2 Trial Comparing Chemoradiation Therapy Regimens in Locally Advanced Pancreatic Cancer. *International Journal of Radiation Oncology - Biology - Physics*, 93(4), 810–818.  
<https://doi.org/10.1016/j.ijrobp.2015.08.026>

Publisher's PDF, also known as Version of record

License (if available):  
CC BY

Link to published version (if available):  
[10.1016/j.ijrobp.2015.08.026](https://doi.org/10.1016/j.ijrobp.2015.08.026)

[Link to publication record in Explore Bristol Research](#)  
PDF-document

This is the final published version of the article (version of record). It first appeared online via Elsevier at <http://www.sciencedirect.com/science/article/pii/S0360301615031740>. Please refer to any applicable terms of use of the publisher.

## University of Bristol - Explore Bristol Research

### General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:  
<http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>

**Table 3. Mean difference in HRQL across all randomised patients between baseline and week 17 (induction chemotherapy)**

Scale	n	Wk 0 $\mu$	Wk 17 $\mu$	Diff	ICI	uCI
<i>Global</i>	58	64.80	68.25	3.45	-1.46	8.36
<i>Functional</i>						
Physical	59	79.89	78.45	-1.44	-5.94	3.06
Role	59	70.90	69.77	-1.13	-8.43	6.17
Emotional	59	75.71	77.68	1.98	-2.77	6.72
Cognitive	59	82.20	78.81	-3.39	-7.64	0.86
Social	58	65.52	70.98	5.46	-1.85	12.77
<i>Symptoms</i>						
Fatigue	59	37.29	37.85	0.56	-6.12	7.25
Nausea	59	14.69	12.71	-1.98	-7.69	3.73
Pain	59	31.36	20.34	<b>-11.02</b>	-18.08	-3.96
Dyspnoea	58	13.22	18.39	5.17	-1.14	11.49
Insomnia	59	34.46	27.12	-7.34	-14.57	-0.12
Appetite	59	36.72	23.16	<b>-13.56</b>	-23.90	-3.22
Constipation	58	18.39	12.64	-5.75	-11.47	-0.03
Diarrhoea	58	20.11	25.29	5.17	-1.75	12.10
Financial	57	21.05	17.54	-3.51	-11.47	4.45
Panc Pain	58	36.83	22.51	<b>-14.32</b>	-21.02	-7.62
Bloating	57	32.75	22.81	-9.94	-17.03	-2.86
Gastro	58	35.92	28.74	-7.18	-16.14	1.78
Taste	58	27.01	32.18	5.17	-4.37	14.72
Indigestion	56	25.60	22.02	-3.57	-12.03	4.88
Flatulence	58	48.85	48.28	-0.57	-11.65	10.50
Weight	58	40.80	30.46	<b>-10.34</b>	-20.62	-0.06
Weak limbs	58	27.01	33.33	6.32	0.08	12.56
Dry mouth	58	32.18	31.03	-1.15	-10.43	8.13
Jaundice	55	16.97	11.82	-5.15	-10.96	0.66
Bowel	58	34.48	34.77	0.29	-7.78	8.35
Image	57	26.02	27.49	1.46	-6.78	9.70
Side effects	49	15.65	30.61	<b>14.97</b>	5.38	24.55
Future	55	58.18	47.88	<b>-10.30</b>	-18.78	-1.83
Planning	57	40.35	33.92	-6.43	-17.58	4.71
Healthcare	57	85.96	89.18	3.22	-4.28	10.71
Sexual	43	50.00	51.94	1.94	-10.23	14.11

Abbreviations:  $\mu$ =mean; ICI=lower 95% confidence interval; uCI=upper 95% confidence interval; Diff=difference between means

NB High scores in function scales (and SaHC) represent better HRQL and higher scores in symptom scales represent worse HRQL. Negative differences in function scales represent HRQL worsening whereas negative differences in symptom scores represents HRQL improvement. Clinically significant differences are highlighted in bold.

**Table 4. Mean difference in HRQL across all randomised patients between week 17 and later timepoints**

Scale	Week 23-17						Week 26-17						Week 39-17					
	n	Wk 17 $\mu$	Wk 23 $\mu$	Diff	ICI	uCI	n	Wk 17 $\mu$	Wk 26 $\mu$	Diff	ICI	uCI	n	Wk 17 $\mu$	Wk 39 $\mu$	Diff	ICI	uCI
<i>Functional</i>																		
GQOL	46	68.84	62.32	-6.52	-12.49	-0.55	46	67.39	61.96	-5.43	-12.76	1.89	37	66.44	61.71	-4.73	-11.62	2.16
Physical	47	77.84	72.06	-5.78	-9.65	-1.91	47	78.55	76.35	-2.20	-6.95	2.55	37	76.76	74.59	-2.16	-6.88	2.55
Role	47	70.92	63.48	-7.45	-15.66	0.77	47	69.15	64.89	-4.26	-13.85	5.34	37	66.22	63.51	-2.70	-12.01	6.61
Emotional	47	78.55	73.17	-5.38	-10.08	-0.68	47	76.95	68.09	-8.87	-15.51	-2.22	38	77.85	68.64	-9.21	-16.49	-1.93
Cognitive	47	80.50	77.66	-2.84	-6.96	1.29	47	79.08	75.89	-3.19	-8.65	2.27	38	76.75	74.12	-2.63	-10.22	4.96
Social	46	69.20	65.58	-3.62	-9.33	2.08	46	66.67	64.86	-1.81	-11.72	8.10	37	63.06	63.06	0.00	-8.49	8.49
<i>Symptoms</i>																		
Fatigue	47	35.22	46.93	<b>11.70</b>	5.34	18.07	47	38.06	40.90	2.84	-3.53	9.20	38	40.35	37.72	-2.63	-10.39	5.12
Nausea	47	12.06	20.21	8.16	1.17	15.14	47	13.12	15.25	2.13	-6.07	10.33	38	11.84	10.53	-1.32	-7.07	4.43
Pain	47	20.92	24.82	3.90	-3.54	11.34	47	21.99	26.24	4.26	-4.73	13.24	38	20.61	31.58	<b>10.96</b>	0.52	21.41
Dyspnoea	46	19.57	23.91	4.35	-2.12	10.82	47	20.57	24.82	4.26	-4.06	12.57	36	22.22	16.67	-5.56	-13.87	2.75
Insomnia	47	26.24	26.24	0.00	-7.36	7.36	46	28.26	31.16	2.90	-7.50	13.30	37	27.93	28.83	0.90	-8.36	10.16
Appetite	46	19.57	39.13	<b>19.57</b>	7.65	31.48	47	23.40	30.50	7.09	-2.02	16.20	37	23.42	26.13	2.70	-7.90	13.30
Constipation	46	14.49	16.67	2.17	-4.56	8.90	46	15.94	18.12	2.17	-3.50	7.85	38	15.79	14.91	-0.88	-7.37	5.61
Diarrhoea	47	19.86	21.99	2.13	-5.34	9.60	46	23.19	23.19	0.00	-8.85	8.85	38	21.93	21.05	-0.88	-7.37	5.61
Financial	46	20.29	22.46	2.17	-5.18	9.52	46	18.12	23.91	5.80	-1.22	12.81	37	20.72	14.41	-6.31	-14.93	2.32
Panc Pain	45	21.85	27.59	5.74	0.72	10.77	46	24.46	27.54	3.08	-3.03	9.19	37	22.45	30.18	7.73	-0.55	16.02
Bloating	45	19.26	24.44	5.19	-2.50	12.87	46	25.36	25.36	0.00	-7.81	7.81	37	20.72	31.53	<b>10.81</b>	0.99	20.63
Gastro	45	25.56	37.78	<b>12.22</b>	2.83	21.61	46	30.80	32.61	1.81	-7.59	11.22	37	27.03	23.87	-3.15	-13.62	7.31
Taste	45	31.11	35.56	4.44	-5.48	14.37	46	36.96	36.23	-0.72	-9.70	8.25	37	29.73	24.32	-5.41	-15.04	4.22
Indigestion	44	20.45	21.97	1.52	-8.25	11.28	43	25.58	17.83	-7.75	-16.94	1.43	37	22.52	30.63	8.11	-2.50	18.72

Flatulence	45	43.70	48.89	5.19	-5.69	16.06	46	47.10	42.75	-4.35	-13.59	4.89	35	53.33	49.52	-3.81	-14.84	7.22
Weight	45	30.37	38.52	8.15	-0.16	16.46	45	29.63	34.81	5.19	-6.88	17.25	37	31.53	31.53	0.00	-9.07	9.07
Weak limbs	45	30.37	31.85	1.48	-5.90	8.86	46	31.16	35.51	4.35	-4.89	13.59	36	33.33	30.56	-2.78	-11.46	5.91
Dry mouth	44	28.79	27.27	-1.52	-9.38	6.35	44	29.55	26.52	-3.03	-13.70	7.64	37	28.83	22.52	-6.31	-14.93	2.32
Jaundice	43	10.08	8.53	-1.55	-6.41	3.30	44	10.23	9.09	-1.14	-6.64	4.37	33	13.64	10.61	-3.03	-11.32	5.26
Bowel	45	31.11	34.07	2.96	-5.12	11.04	46	35.51	40.22	4.71	-3.21	12.63	37	37.39	45.50	8.11	-0.84	17.05
Image	45	25.93	24.81	-1.11	-7.37	5.15	45	27.78	34.07	6.30	-2.53	15.12	37	28.83	34.68	5.86	-2.55	14.26
Side effects	45	28.15	37.78	9.63	3.36	15.90	45	34.07	33.33	-0.74	-9.41	7.93	37	35.14	30.63	-4.50	-12.86	3.85
Future	45	48.89	57.78	8.89	-1.22	18.99	46	51.45	57.97	6.52	-3.18	16.22	37	50.45	56.76	6.31	-4.76	17.37
Planning	44	34.09	38.64	4.55	-4.08	13.18	46	37.68	38.41	0.72	-9.81	11.26	37	38.74	42.34	3.60	-7.13	14.34
Healthcare	45	89.63	91.48	1.85	-6.77	10.47	46	92.03	92.03	0.00	-7.60	7.60	37	92.34	84.23	-8.11	-18.96	2.74
Sexual	36	53.70	60.65	6.94	-4.20	18.09	38	53.95	53.95	0.00	-11.32	11.32	30	49.44	58.33	8.89	-3.95	21.73

Abbreviations:  $\mu$ =mean; lCI=lower 95% confidence interval; uCI=upper 95% confidence interval; Diff= difference between means; scale abbreviations as shown in Table 1.

NB High scores in functioning scales (and SatHC) represent better HRQL and higher scores in symptom scales represent worse HRQL. Negative differences in functioning scales (and SatHC) represent HRQLworsening whereas negative differences in symptom scores represent HRQLimprovement. Clinically significant differences are highlighted in bold.

**Table 5. Difference in HRQL between week 17 and later timepoints by trial arm**

Scale	Week 23-Week 17								Week 26-Week 17						Week 39-Week 17								
	Capecitabine			Gemcitabine			z	p	Capecitabine			Gemcitabine			z	p	Capecitabine		Gemcitabine		z	p	
	Median score week 17	n	Median difference in score (range)	Median score week 17	n	Median difference in score (range)			Median difference in score (range)	n	Median difference in score (range)	n	Median difference in score (range)	Median difference in score (range)			n	Median difference in score (range)	n	Median difference in score (range)			n
<i>Func.</i>																							
GQOL	66.7	23	0.0 (-33.3,41.7)	66.7	23	-16.7 (50.0,33.3)	1.70	0.090	23	0.0 (-50.0,50.0)	23	0.0 (-83.3,33.3)	0.57	0.571	23	0.0 (-41.7,33.3)	14	-8.3 (-58.3,33.3)	1.21	0.227			
Physical	86.7	23	0.0 (-40.0,26.7)	73.3	24	-10.0 (-33.3,20.0)	1.58	0.114	23	0.0 (-33.3,26.7)	24	0.0 (-66.7,26.7)	-0.24	0.808	22	0.0 (-13.3,26.7)	15	-6.7 (-40.0,13.3)	1.28	0.199			
Role	83.3	23	0.0 (-50.0,66.7)	66.7	24	-16.7 (-66.7,66.7)	1.11	0.268	23	0.0 (-50.0,66.7)	24	0.0 (-100.0,66.7)	1.13	0.259	22	0.0 (-50.0,50.0)	15	0.0 (-66.7,33.3)	1.22	0.223			
Emotional	83.3	23	0.0 (-58.3,16.7)	75.0	24	0.0 (-58.3,25.0)	-0.17	0.869	23	0.0 (-33.3,25.0)	24	0.0 (-83.3,41.7)	1.67	0.094	23	-8.3 (-50.0,16.7)	15	-8.3 (-75.0,50.0)	0.53	0.598			
Cognitive	83.3	23	0.0 (-16.7,16.7)	83.3	24	0.0 (-33.3,33.3)	2.10	<b>0.036</b>	23	0.0 (-33.3,33.3)	24	0.0 (-66.7,16.7)	1.19	0.233	23	0.0 (-66.7,33.3)	15	-16.7 (-50.0,33.3)	2.54	<b>0.011</b>			
Social	83.3	23	0.0 (-66.7,50.0)	66.7	23	0.0 (-33.3,33.3)	0.19	0.848	23	0.0 (-66.7,66.7)	23	0.0 (-100.0,33.3)	0.80	0.422	23	0.0 (-66.7,50.0)	14	0.0 (-66.7,33.3)	-0.02	0.987			
<i>Symp.</i>																							
Fatigue	33.3	23	11.1 (-33.3,44.4)	33.3	24	16.7 (-33.3,55.6)	-1.99	<b>0.046</b>	23	0.0 (-44.4,33.3)	24	0.0 (-33.3,77.8)	-0.45	0.652	23	-11.1 (-66.7,33.3)	15	-11.1 (-22.2,44.4)	-1.47	0.142			
Nausea	0.0	23	0.0 (-33.3,50.0)	16.7	24	8.3 (-50.0,83.3)	-1.00	0.320	23	0.0 (-33.3,50.0)	24	0.0 (-66.7,100.0)	0.38	0.700	23	0.0 (-33.3,50.0)	15	0.0 (-33.3,0.0)	1.83	0.067			
Pain	16.7	23	0.0 (-33.3,33.3)	16.7	24	0.0 (-66.7,83.3)	-1.36	0.174	23	0.0 (-50.0,66.7)	24	0.0 (-66.7,100.0)	-0.79	0.431	23	16.7 (-66.7,66.7)	15	16.7 (-50.0,66.7)	-0.61	0.545			
Dyspnoea	0.0	22	0.0 (-66.7,33.3)	33.3	24	0.0 (-33.3,66.7)	-1.52	0.129	23	0.0 (-66.7,66.7)	24	0.0 (-33.3,66.7)	-1.19	0.234	21	0.0 (-66.7,33.3)	15	0.0 (-33.3,66.7)	-1.38	0.167			
Insomnia	33.3	23	0.0 (-66.7,33.3)	0.0	24	0.0 (-33.3,66.7)	-0.48	0.635	22	0.0 (-66.7,33.3)	24	0.0 (-66.7,100.0)	0.12	0.907	22	0.0 (-66.7,66.7)	15	0.0 (-33.3,66.7)	-0.96	0.335			
Appetite	0.0	23	0.0 (-66.7,100.0)	33.3	23	33.3 (-66.7,100.0)	-1.75	0.081	23	0.0 (-66.7,100.0)	24	0.0 (-33.3,66.7)	-0.80	0.421	22	0.0 (-33.3,100.0)	15	0.0 (-66.7,66.7)	0.12	0.904			
Constipation	0.0	22	0.0 (-33.3,66.7)	0.0	24	0.0 (-33.3,33.3)	-0.64	0.525	22	0.0 (-33.3,33.3)	24	0.0 (-33.3,33.3)	-0.65	0.516	23	0.0 (-66.7,33.3)	15	0.0 (-33.3,33.3)	-0.66	0.511			
Diarrhoea	0.0	23	0.0 (-33.3,33.3)	33.3	24	0.0 (-66.7,66.7)	0.42	0.678	22	0.0 (-33.3,66.7)	24	0.0 (-66.7,66.7)	0.03	0.980	23	0.0 (-33.3,33.3)	15	0.0 (-33.3,33.3)	-0.21	0.831			
Financial	0.0	23	0.0 (-33.3,33.3)	0.0	23	0.0 (-33.3,100.0)	-1.12	0.262	23	0.0 (-33.3,66.7)	23	0.0 (-33.3,66.7)	-0.87	0.383	23	0.0 (-66.7,66.7)	14	0.0 (-66.7,33.3)	0.51	0.613			
Panc Pain	8.3	23	0.0 (-33.3,33.3)	25.0	22	8.3 (-16.7,50.0)	-0.47	0.640	23	0.0 (-41.7,50.0)	23	0.0 (-33.3,50.0)	0.13	0.894	22	8.3 (-50.0,58.3)	15	0.0 (-33.3,75.0)	0.19	0.851			
Bloating	0.0	23	0.0 (-33.3,33.3)	33.3	22	0.0 (-33.3,100.0)	-2.11	<b>0.035</b>	23	0.0 (-33.3,33.3)	23	0.0 (-66.7,66.7)	-0.62	0.536	22	0.0 (-66.7,100.0)	15	0.0 (-33.3,33.3)	0.42	0.674			
Gastro	16.7	23	0.0 (-16.7,100.0)	33.3	22	8.3 (50.0,66.7)	-0.36	0.718	23	0.0 (-66.7,66.7)	23	0.0 (-50.0,100.0)	0.35	0.726	22	0.0 (-66.7,66.7)	15	-16.7 (-50.0,50.0)	1.66	0.097			

Taste	33.3	23	0.0 (-100.0,66.7)	33.3	22	0.0 (- 33.3,100.0)	-0.91	0.361	23	0.0 (-66.7,66.7)	23	0.0 (-66.7,66.7)	-0.60	0.546	22	0.0 (-66.7,33.3)	15	0.0 (-66.7,33.3)	-0.34	0.732
Indigestion	0.0	22	0.0 (-33.3,100.0)	33.3	22	0.0 (-33.3,66.7)	0.11	0.915	21	0.0 (-100.0,66.7)	22	0.0 (-66.7,33.3)	1.17	0.244	22	0.0 (-66.7,100.0)	15	0.0 (0.0,33.3)	-0.45	0.651
Flatulence	33.3	23	0.0 (-33.3,100.0)	33.3	22	0.0 (-100,100)	-0.01	0.990	23	0.0 (-100.0,66.7)	23	0.0 (-66.7,33.3)	0.30	0.761	21	0.0 (-66.7,100.0)	14	0.0 (-33.3,33.3)	0.19	0.852
Weight	33.3	23	0.0 (-33.3,66.7)	33.3	22	0.0 (-66.7,66.7)	-1.02	0.310	22	0.0 (-66.7,66.7)	23	0.0 (-100,100)	-0.73	0.467	22	0.0 (-33.3,66.7)	15	0.0 (-66.7,66.7)	0.34	0.738
Weak limbs	33.3	23	0.0 (-66.7,33.3)	33.3	22	0.0 (-33.3,66.7)	-1.76	0.078	23	0.0 (-66.7,33.3)	23	0.0 (-33.3,100.0)	-1.37	0.169	21	0.0 (-33.3,33.3)	15	0.0 (-33.3,66.7)	-1.62	0.104
Dry mouth	33.3	22	0.0 (-66.7,33.3)	33.3	22	0.0 (-66.7,33.3)	-2.18	<b>0.029</b>	22	0.0 (-66.7,66.7)	22	0.0 (-66.7,100.0)	-1.23	0.220	22	0.0 (-66.7,0.0)	15	0.0 (-33.3,33.3)	-3.44	<b>0.001</b>
Jaundice	0.0	22	0.0 (-33.3,50.0)	0.0	21	0.0 (-50.0,33.3)	0.62	0.536	22	0.0 (-50.0,66.7)	22	0.0 (-33.3,16.7)	-0.05	0.956	19	0.0 (-66.7,50.0)	14	0.0 (-66.7,33.3)	-0.12	0.907
Bowel	33.3	23	0.0 (-33.3,66.7)	50.0	22	0.0 (-50.0,66.7)	1.02	0.306	23	0.0 (-50.0,66.7)	23	0.0 (-50.0,50.0)	-0.45	0.652	22	0.0 (-50.0,66.7)	15	0.0 (-33.3,50.0)	0.00	1.000
Image	33.3	23	0.0 (-33.3,50.0)	0.0	22	0.0 (-66.7,33.3)	0.51	0.608	23	0.0 (-50.0,50.0)	22	0.0 (-50.0,100.0)	-0.28	0.778	22	0.0 (-50.0,33.3)	15	0.0 (-16.7,66.7)	-2.29	<b>0.022</b>
Side effects	33.3	23	0.0 (-33.3,33.3)	33.3	22	0.0 (- 33.3,66.7)	-0.55	0.584	23	0.0 (-66.7,33.3)	22	0.0 (-33.3,100.0)	-0.15	0.883	22	0.0 (-33.3,33.3)	15	0.0 (-33.3,33.3)	-0.02	0.987
Future	66.7	23	0.0 (-33.3,66.7)	33.3	22	0.0 (-66.7,100.0)	-0.32	0.747	23	0.0 (-33.3,66.7)	23	0.0 (-33.3,100.0)	-2.13	<b>0.033</b>	22	0.0 (-33.3,100.0)	15	0.0 (-66.7,66.7)	-0.52	0.600
Planning	33.3	23	0.0 (-33.3,66.7)	33.3	21	0.0 (-33.3,66.7)	0.20	0.841	23	0.0 (-100.0,66.7)	23	0.0 (-66.7,66.7)	-0.85	0.396	22	0.0 (-66.7,100.0)	15	0.0 (-33.3,66.7)	-0.80	0.426
Healthcare	100.0	23	0.0 (-100,100)	100.0	22	0.0 (-16.7,83.3)	-0.76	0.449	23	0.0 (- 100.0,100.0)	23	0.0 (-33.3,50.0)	-0.25	0.803	22	0.0 (-100.0,16.7)	15	0.0 (-50.0,50.0)	-1.91	0.056
Sexual	41.7	20	0.0 (-66.7,66.7)	66.7	16	0.0 (-100.0,83.3)	-0.07	0.941	20	0.0 (0.0,66.7)	18	0.0 (-100.0,83.3)	1.24	0.213	17	0.0 (-33.3,33.3)	13	0.0 (-100.0,83.3)	-0.55	0.583

NB: Negative differences in functioning scales (and SatHC) represent HRQL worsening whereas negative differences in symptom scores represents HRQL improvement. Abbreviations as shown in Table 1. P values < 0.05 are in bold.

**Table 6. Mean week 23 QLQ-PAN26 scale scores by those with and without any CTCAE grade 3 or 4 adverse events during CRT**

PAN 26 scale	No grade 3 or 4 adverse events during CRT				Any Grade 3 or 4 adverse events during CRT			
	n	Mean	Lower 95% CI	Upper 95% CI	n	Mean	Lower 95% CI	Upper 95% CI
Pancreatic pain*	38	23.90	16.93	30.88	10	36.67	18.20	55.14
Bloating*	38	20.18	11.52	28.83	10	36.67	15.79	57.55
Gastrointestinal*	38	32.89	21.40	44.39	10	58.33	35.68	80.99
Taste loss	38	34.21	24.19	44.24	10	40.00	10.69	69.31
Indigestion	38	21.05	11.38	30.73	10	23.33	0.71	45.95
Flatulence	38	45.61	34.98	56.25	10	50.00	26.83	73.17
Weight*	38	31.58	20.20	42.96	10	63.33	32.65	94.01
Weak limbs*	38	26.32	17.43	35.20	10	53.33	30.30	76.37
Dry mouth	37	28.83	18.63	39.03	10	23.33	3.70	42.96
Jaundice	38	7.89	2.84	12.95	10	8.33	2.05	14.62
Altered bowel habit*	38	28.51	18.41	38.61	10	58.33	33.67	82.99
Poor body image	38	25.44	14.80	36.07	10	25.00	3.05	46.95
Side effects of treatment	38	35.96	27.37	44.56	10	36.67	12.95	60.38
Future health concern*	38	51.75	39.89	63.62	10	73.33	48.71	97.96
Forward planning limited*	37	33.33	21.91	44.75	10	56.67	37.04	76.30
Satisfaction with healthcare	38	92.11	85.52	98.69	10	91.67	81.53	101.80
Sexual dissatisfaction	31	59.14	43.45	74.83	7	66.67	32.20	101.13

\*indicates a difference in means of more than 10 points